Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3108-3116

  Ma, Xiaoli ^a,b   Ma, Quanfu ^a   Liu, Jia ^a   Tian, Yuan ^a   Wang, Beibei ^a   Taylor, Kathryn M ^c   Wu, Peng ^a   Wang, Daowen ^a   Xu, Gang ^a   Meng, Li ^a   Wang, Shixuan ^a   Ma, Ding ^a   Zhou, Jianfeng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APICIDINE; CASPASE 3; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; ZINC;

APOPTOSIS; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INDUCTION; HUMAN; HUMAN CELL; LIV 1 GENE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, ANTISENSE; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; UTERINE CERVICAL NEOPLASMS; ZINC;

EID: 70949095250     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0772     Document Type: Article

References (32)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784 (Pubitemid 44348499)
2. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7:583-598 (Pubitemid 46690964)
3. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90. (Pubitemid 46087907)
4. Johnstone RW. Histonedeacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-299 (Pubitemid 37361445)
5. Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004;3:779-788
6. Deiss LP, Kimchi A. A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal. Science 1991;252:117-120 (Pubitemid 21916950)
7. Papeleu P, Vanhaecke T, Elaut G, et al. Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit Rev Toxicol 2005;35:363-378
8. Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol 2006;102p:348-355 (Pubitemid 44063583)
9. Rajan S, Cacalano G, Bryan R, et al. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factor. Am J Respir Cell Mol Biol 2000;23:304. (Pubitemid 30701839)
10. Zhou J, Gao Q, Chen G, et al. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res 2005;11:8431-8439 (Pubitemid 41746958)
11. Hofmann ER, Boyanapalli M, Lindner DJ, et al. Thioredoxin reductase mediates cell death effects of the combination of β interferon and retinoic acid. Mol Cell Biol 1998;18:6493-6504 (Pubitemid 28500539)
12. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 1967;26:365-369
13. Rozen S, Skaletsky H. Primer3 on the WWW for general users and biologistprogrammers. In: Krawetz S, Misener S, editors. Bioinformatics methods and protocols: Methods in molecular biology. Totowa (NJ): Humana Press; 2000, p. 365-386
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) Method. Methods 2001;25:402-408 (Pubitemid 34164012)
15. Gao Q, Huang X, Tang D, et al. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Apoptosis 2006;11:1789-1800 (Pubitemid 44371052)
16. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304.
17. Taylor KM, Morgan HE, Johnson A, Hadley LJ, Nicholson RI. Structure- function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochem J 2003;375: 51-59 (Pubitemid 37255381)
18. Taylor KM, Nicholson RI. The LZT proteins;the LIV-1 subfamily of zinc transporters. Biochim Biophys Acta 2003;1611:16-30.
19. Gee KR, Zhou ZL, Ton-That D, Sensi SL, Weiss JH. Measuring zinc in living cells. A new generation of sensitive and selective fluorescent probes. Cell Calcium 2002;31:245-251
20. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-545
21. Mariadac JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostain A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000;60:4561-4572
22. Taylor KM. LIV-1 breast cancer protein belongs to a new family of histidine-rich membrane proteins with potential to control intracellular Zn2+ homeostasis. IUBMB Life 2000;49:294-353
23. Grit K, Weiser AA, Andreas R, et al. Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients. Int J Cancer 2005;117:961-973
24. Susumu Y, Chiemi M, Toshiyuki F, et al. Zinc transporter LIV1 controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature 2004;429:298-302.
25. Clegg MS, Hanna LA, Niles BJ, Momma TY, Keen CL. Zinc deficiency-induced cell death. IUBMB Life 2005;57:661-669
26. Chimienti F, Aouffen M, Favier A, Seve M. Zinc homeostasis-regulating proteins: new drug targets for triggering cell fate. Curr Drug Targets 2003; 4:323-338 (Pubitemid 36443251)
27. Fraker PJ. Roles for cell death in zinc deficiency. J Nutr 2005;135: 359-362 (Pubitemid 40365188)
28. Seve M, Chimienti F, Favier A. Role of intracellular zinc in programmed cell death. Pathol Biol (Paris) 2002;50:212-221
29. Truong-Tran AQ, Carter J, Ruffin RE, Zalewski PD. The role of zinc in caspase activation and apoptotic cell death. Biometals 2001;14:315-330
30. Henshall SM, Afar DE, Rasiah KK, et al. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-6012
31. Lee R, Woo W, Wu B, Kummer A, Duminy H, Xu Z. Zinc accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors is accompanied by an altered expression of ZnT-1 and metallothionein. Exp Biol Med (Maywood) 2003;228:689-696
32. Hasumi M, Suzuki K, Matsui H, Koike H, Ito K, Yamanaka H. Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. Cancer Lett 2003;200:187-195